Stay updated on SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.3.3 was added to the footer, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check23 days agoChange DetectedThe history version now includes new core content sections: Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Arms and Interventions, and Study Status. These updates expand the data on safety, outcomes, and trial design for NCT03924869 (version dated 2025-12-11, preceding version 2025-11-24, entry 167).SummaryDifference0.2%

- Check44 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed from the Record History page.SummaryDifference0.0%

- Check52 days agoChange DetectedThe NIH funding/status notice in the page footer was removed, a non-functional site-wide update that does not affect core trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check66 days agoChange DetectedThe new screenshot shows the record history with version entries that appear identical to the previous image, indicating no substantive changes to the study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check95 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference5%

Stay in the know with updates to SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.